OSLO, Norway, April 7, 2026 - Lytix Biopharma AS ("Lytix" or the "Company"), a
clinical-stage immuno-oncology company developing novel intratumoral cancer
therapies, today announced the appointment of Renée Christine Amundsen as Chief
Operating Officer (COO), effective immediately. Her appointment comes at a
pivotal point as the Company continues to advance its clinical pipeline and
sharpen its operational focus for the next stage of growth.

Amundsen brings more than 20 years of global leadership experience across the
pharmaceutical and life sciences industries. She has led teams and operations
through periods of scale and complexity, with a focus on translating strategy
into execution within innovation-driven healthcare companies.

"We are entering an important phase for Lytix as we continue advancing our
clinical programs and building the capabilities required to deliver long-term
value," said Øystein Rekdal, Chief Executive Officer of Lytix Biopharma. "Renée
brings strong execution capabilities that will enhance operational performance
and support the company's continued growth."

As Chief Operating Officer, Amundsen will lead global operations, focusing on
preparing the Company for late-stage development and ensuring disciplined
execution across its clinical programs, including ruxotemitide and LTX-401,
while maintaining alignment across functions, timelines, and cost. 

Prior to joining Lytix, Amundsen served as Corporate Vice President at Novo
Nordisk and held senior leadership roles at Merck KGaA, where she led
large-scale commercial and operational initiatives and managed full P&L
responsibility across multiple markets. 

"I'm very pleased to be joining Lytix at such a meaningful point in its
development," said Amundsen. "The company has built a strong foundation, and I
look forward to working with the team to support continued clinical progress and
ensure we are well positioned for the opportunities ahead."

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.

For more information, visit www.lytixbiopharma.com